Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
about
Treatment for small cell lung cancer, where are we now?-a reviewEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSurrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouseIndividual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.Surrogate endpoints for overall survival in advanced non-small-cell lung cancer patients with mutations of the epidermal growth factor receptor gene.Predictive power to assist phase 3 go/no go decision based on phase 2 data on a different endpoint.Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancerPatterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centresCellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Modified one-day etoposide and cisplatin combination for previously untreated extensive-disease small-cell lung cancer: A retrospective evaluation of 36 cases.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.The Globalization of Cooperative Groups.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapyEstimation of expectedness: predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer.Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer.Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database.Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer.[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experienceSomatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy.Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Should patients with laryngeal small cell neuroendocrine carcinoma receive prophylactic cranial irradiation?Clinical significance of post-progression survival in lung cancerSurrogate endpoints for overall survival in lung cancer trials: a review.Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement.Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaImpact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points.Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer.Another disappointing result, but how good is it?Survival analyses in lung cancer.Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study.Immune checkpoint inhibitors and small cell lung cancer: what’s new?
P2860
Q26767023-9A52D111-F362-49F7-A691-D92F4E3D142EQ26786618-18A97AFC-4DC6-4973-AB32-3CB1D3459A77Q30627447-CC465FAB-3AA2-4D4B-9022-19ADBE9AE195Q30754691-05A04304-0D13-4E34-9E14-8D3B46F35D05Q30833179-155C54FF-372B-402B-B037-5CD965A5E159Q33933021-5F5C6432-7CF8-43F3-B522-F0D58D66004BQ34149644-C134F4C1-ACAE-42E1-883B-F58037276E64Q34653756-FE23E210-D99B-4FD4-B41A-F35904553415Q34866341-11C81278-AF86-4465-B56B-DDB51B94D3CBQ34981488-97BE708A-3D82-4E52-8BBF-71DF0293EB76Q35655447-985DFD32-033C-4C3A-9D61-52CAB975AA43Q35802946-9037867A-D378-42AD-AA51-579B7A881E34Q35825822-CCF128EE-98F3-4F8B-99E9-BB3822084A80Q36119749-008E7BA3-1D4D-43A7-B6DD-22B21757BA30Q36349459-F4C51CD6-11E7-4E87-8F8A-C5A4A98D2573Q36490413-664E0E7F-181D-4A33-B7B3-7CC00D7A8232Q36584405-5BCF2C62-F427-4161-AC55-A9F5E096D6F5Q36594253-9F106ADF-32AE-4A52-8CC7-94736BA91688Q36680046-9218A342-930F-4809-AB6E-8E7050C25E26Q36689055-FDF7948E-1A2A-463A-A0D1-D8D798EE8B9DQ36962582-FEA2456C-2C57-4EF4-AD1B-ADECC7AF08DBQ37190242-2705A842-2333-4117-B443-2E6B88845424Q37389608-EBDB984C-F0BA-41F0-9135-925F12FD009CQ38259501-132C5556-C432-4156-A87A-B71C6DFD44C6Q38623633-E3467EDD-5E70-4100-AD6B-86D5A2B80450Q38669447-1A0E53F8-7A2D-4FF8-9DCE-461060B5FD8FQ38841987-ED845D97-7A6D-4F05-B202-F08160A76923Q39233456-FB54B02C-01D8-4374-B1DE-EB02287A780AQ39572955-4F73D998-94D5-4ECC-9723-7C47C1C5B974Q39583147-7CC868D1-B375-4F2D-AE22-BD9C8C3D3AB4Q40595362-1FAF5D87-61E6-4F4E-A1C8-B5361025AD4DQ41192457-7EB54198-9B0F-44EE-9B28-26987786D796Q41768357-4018D219-CB01-4F2D-87BD-61FAE1028745Q41865845-CF4C3672-70CA-4A66-96EE-59D951E3023CQ41962742-95D2CFD1-E943-4C0D-8DF3-E78E9833ED39Q42332732-F2CE8568-480D-4A92-B02C-E33C97F2C5DCQ42344282-A3DB19E2-E472-4921-A10F-AF1527532828Q43623679-A1C9DCDD-2F6D-4EB2-A631-8DEBAFB8E56DQ55287013-DDB5C78B-1C99-4F2D-A009-BCEC1BC7D357
P2860
Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tumor response and progression ...... Cancer Treatment Group trials.
@ast
Tumor response and progression ...... Cancer Treatment Group trials.
@en
Tumor response and progression ...... Cancer Treatment Group trials.
@nl
type
label
Tumor response and progression ...... Cancer Treatment Group trials.
@ast
Tumor response and progression ...... Cancer Treatment Group trials.
@en
Tumor response and progression ...... Cancer Treatment Group trials.
@nl
prefLabel
Tumor response and progression ...... Cancer Treatment Group trials.
@ast
Tumor response and progression ...... Cancer Treatment Group trials.
@en
Tumor response and progression ...... Cancer Treatment Group trials.
@nl
P2093
P2860
P356
P1433
P1476
Tumor response and progression ...... Cancer Treatment Group trials.
@en
P2093
Alex A Adjei
James E Krook
James R Jett
John W Kugler
Julian R Molina
Nathan R Foster
Steven E Schild
Sumithra J Mandrekar
Yingwei Qi
P2860
P304
P356
10.1002/CNCR.25526
P407
P577
2010-10-19T00:00:00Z